20:36 , Sep 20, 2018 |  BC Extra  |  Company News

FDA: No new safety concerns for Acadia's PD psychosis drug

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) rose $4.01 (27%) to $19.11 in afternoon trading Thursday, adding more than $500 million in market cap, after an FDA safety review of the company's Nuplazid pimavanserin found postmarketing safety data...
22:41 , Jul 20, 2018 |  BC Extra  |  Company News

Management tracks: Merck KGaA, Aeglea

Merck KGaA (Xetra:MRK) hired Maria Rivas as SVP, head of global medical affairs. She was SVP, head of medical affairs at Merck & Co. Inc. (NYSE:MRK). Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said interim CEO...
22:00 , Jun 18, 2018 |  BC Extra  |  Company News

Management tracks: Ionis, Albireo

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) hired Damien McDevitt as CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was general...
20:39 , May 11, 2018 |  BioCentury  |  Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...
19:52 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Acadia's Parkinson drug

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) sank 22% to $15.20 on April 25 after CNN reported that FDA is re-examining the safety of Nuplazid pimavanserin, which is approved to treat Parkinson's disease psychosis (PDP). An FDA spokesperson...
20:27 , Apr 25, 2018 |  BC Extra  |  Company News

FDA re-evaluating Acadia's Nuplazid

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) sank $4.27 (22%) to $15.20 on Wednesday after CNN reported that FDA is re-examining the safety of Nuplazid pimavanserin, which is approved to treat Parkinson's disease psychosis (PDP). An FDA spokesperson...
13:47 , Apr 13, 2018 |  BC Week In Review  |  Company News

Safety concerns for Acadia's Nuplazid resurface

On April 9, CNN called out a November 2017 safety report from the non-profit group Institute for Safe Medication Practices (ISMP), which identified 244 deaths among 2,236 adverse event reports filed for patients taking Nuplazid...
21:02 , Apr 9, 2018 |  BC Extra  |  Company News

Acadia falls on Nuplazid safety concerns

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) fell $5.03 (23%) to $16.50 on Monday after CNN called out a November 2017 safety report from the non-profit group Institute for Safe Medication Practices (ISMP), which identified 244 deaths among...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
00:03 , Dec 16, 2017 |  BC Extra  |  Company News

Management tracks: Chugai, bioMérieux

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said President and COO Tatsuro Kosaka will become president and CEO. He succeeds CEO Osamu Nagayama, who will remain chairman. Diagnostics company bioMérieux S.A. (Euronext:BIM) said Deputy CEO Alexandre Mérieux will...